Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02231593 · ClinicalTrials.gov registry record
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
A clinical trial, sponsored by Ipsen.
- Completed
- Registry status
- 71
- Enrollment target
NCT02231593: Completed study, sponsored by Ipsen.
NCT02231593 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02231593 has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level - IGF-1 - Tumour). SAGIT is a Clinician-Reported Outcomes (ClinROs) tool developed to describe patients with acromegaly. This study will determine the potential use of a finalised operational version for patient classification in clinical practice and studies. In addition, this study intends to carry out a qualitative evaluation of the acceptability of SAGIT by the practicing endocrinologist in terms of relevance, ease of use, applicability and usefulness of the tool in practice.
Interventions
- OTHER SAGIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-05 |
What the finished NCT02231593 record still lists
NCT02231593 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SAGIT is the first listed.
NCT02231593 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02231593 about?
NCT02231593 is a clinical study titled "SAGIT for Classification of Patients With Acromegaly in Clinical Practice". The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level - IGF-1 - Tumour). SAGIT is a Clinician-Reported Outcomes (ClinROs) tool developed to describe patients with acromegaly. This study will determine the potential use of a finalised...
What is the current status of trial NCT02231593?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2013-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02231593?
The interventions under investigation include: SAGIT (OTHER).
Who is sponsoring clinical trial NCT02231593?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia